European (ethnic group)
European Commission Imposes €463 Million Fine on Teva for Anti-Competitive Practices in MS Drug Market
Teva, European Commission, fine, MS drug, competition tactics, Copaxone, market dominance
Astellas Withdraws European Application for Geographic Atrophy Treatment Izervay
Astellas, Izervay, geographic atrophy, European application withdrawal, avacincaptad pegol
Merck’s KEYTRUDA Receives 30th European Approval for Gynecologic Cancers
KEYTRUDA, pembrolizumab, European Commission, gynecologic cancers, endometrial cancer, cervical cancer, cancer treatment, immunotherapy.
European Commission’s Reconsideration of Translarna’s Marketing Authorization: A Critical Turning Point for Duchenne Muscular Dystrophy Treatment
Translarna, Duchenne muscular dystrophy, European Commission, EMA, CHMP, conditional marketing authorization, drug approval, regulatory decisions
Pfizer Secures EU Approval for TALZENNA in Combination with XTANDI for Metastatic Castration-Resistant Prostate Cancer
TALZENNA, XTANDI, metastatic castration-resistant prostate cancer (mCRPC), PARP inhibitor, European Commission approval, prostate cancer treatment.
European Medicines Agency Investigates Potential Link Between Hair Loss Drugs and Suicidal Thoughts
EMA, hair loss drugs, finasteride, dutasteride, suicidal thoughts, psychiatric side effects, European Medicines Agency
Kurma Partners Secures €140M for Biofund IV, Aiming for €250M to Fuel European Healthcare Innovation
Kurma Partners, Biofund IV, Healthcare Innovation, Venture Capital, European Biotech, Healthcare Investment
Remedee Labs Secures European Approval for Groundbreaking Fibromyalgia Wristband Therapy
Remedee Labs, fibromyalgia, wristband therapy, European approval, non-pharmaceutical treatment, millimeter-wave technology, endorphin stimulation
Capricor Secures $35M Deal for European Rights to DMD Therapy Ahead of FDA Application
Capricor Therapeutics, Duchenne muscular dystrophy (DMD), cell therapy, FDA application, European rights, $35M deal
European Court Suspends EC’s Decision to Revoke Ocaliva’s Marketing Authorization
Ocaliva, European Court, EC decision, marketing authorization, primary biliary cholangitis, PBC, Advanz Pharma